 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12345678910111213...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Journal: Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. (Pubmed Central) - Aug 15, 2024
P.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer. (Pubmed Central) - Aug 15, 2024
Cetuximab in combination with FOLFIRI/FOLFOX is the standard first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)...REV1 p.R704Q mutation caused decreased stability and degradation of REV1 protein, as well as dysfunction of p.R704Q protein. REV1 p.R704Q mutation activates autophagy and mediates cetuximab resistance; further, inhibition of autophagy could reverse cetuximab resistance.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy. (Pubmed Central) - Aug 15, 2024
Pharmacological inhibition of MCT1, with AR-C155858, reduces the uptake and oxidation of lactate and impairs growth capacity in cetuximab-resistant LIM1215 cells both in vitro and in vivo. This study identifies MCT1-dependent lactate utilization as a clinically actionable, metabolic vulnerability to overcome KRAS-mutant-mediated acquired resistance to anti-EGFR therapy in CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kisqali (ribociclib) / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells. (Pubmed Central) - Aug 15, 2024
Investigating the combined effect of triplet therapy using the calculated combination index (CI) showed that ribociclib had a synergistic effect with encorafenib-cetuximab when applied to PDCs with a concurrent BRAF/PTEN mutation. Our results suggest that combining the CDK4/6 inhibitor with the BRAF/EGFR inhibitor
- | Krazati (adagrasib) / BMS
Journal: Adagrasib (Krazati) for colorectal cancer. (Pubmed Central) - Aug 13, 2024
Our results suggest that combining the CDK4/6 inhibitor with the BRAF/EGFR inhibitor No abstract available
- | Journal: Current treatments for oropharyngeal squamous cell carcinoma and the move towards molecular therapy. (Pubmed Central) - Aug 13, 2024
No abstract available Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently.
- | Opdivo (nivolumab) / BMS
Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma. (Pubmed Central) - Aug 13, 2024
Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently. The frequency of natural killer cells was associated with nivolumab response in patients with prior cetuximab use, but not in cetuximab-na
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Head-to-Head, Metastases: Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer. (Pubmed Central) - Aug 12, 2024
CTS evaluated OS non-inferiority (predefined margin of 1.25) in 1,000 trials, each with 2,000 virtual patients receiving Q2W or Q1W cetuximab (1:1), and demonstrated non-inferiority in 94% of cases. Taken together, these analyses provide model-based evidence for clinical non-inferiority of Q2W vs. Q1W cetuximab in mCRC with potential benefits to patients and healthcare providers.
- | Retrospective data, Journal: A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases. (Pubmed Central) - Aug 12, 2024
Resection or ablation (R/A)+SingleCT, S1, and Cetuximab + intensified fluorouracil-based combination chemotherapy (ICTFU) were identified as the best treatments...The top three treatments were: Atezolizumab + Bevacizumab + fluorouracil-based combination chemotherapy (CTFU), TAS-102+bevacizumab, Bevacizumab + ICTFU...Regarding maintenance treatment, Bevacizumab + SingleCT and Adavosertib were the best options for OS and PFS, respectively...Monotherapy may be preferred choice for maintenance treatment. Combination therapy resulted in more SAEs when compared to standard chemotherapy.
- | Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer. (Pubmed Central) - Aug 10, 2024
Combination therapy resulted in more SAEs when compared to standard chemotherapy. No abstract available
- | Opdivo (nivolumab) / BMS
Journal: Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report. (Pubmed Central) - Aug 10, 2024
This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study (clinicaltrials.gov) - Aug 9, 2024
P2, N=34, Recruiting, Sponsor: Sun Yat-sen University
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study. (Pubmed Central) - Aug 7, 2024
The maintenance regimen consisted of 6-12 cycles of cetuximab plus irinotecan (Phase 1) and cetuximab (Phase 2)...Innovative cetuximab-based maintenance therapy showed a trend toward improving the prognosis of mCRC patients with RAS and BRAF wild-type, while the toxic side effects of maintenance therapy were manageable. https://www.chictr.org.cn, identifier ChiCTR2000040940.
- ||| BND-35 / Biond Biologics
Enrollment open, Combination therapy, Metastases: BND-35-001: A Study of BND-35 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 7, 2024
P1, N=280, Recruiting, Sponsor: Biond Biologics
https://www.chictr.org.cn, identifier ChiCTR2000040940. Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial, Combination therapy, Metastases: ONO-7913-04: The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer (clinicaltrials.gov) - Aug 6, 2024
P1, N=65, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- Erbitux (cetuximab) / Eli Lilly, Braftovi (encorafenib) / Pfizer
Digital sequential imaging of eruptive naevi induced by Encorafenib and Cetuximab for Colorectal Carcinoma (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2663;
Not yet recruiting --> Recruiting It highlights the benefit of careful dermatological surveillance with digital sequential imaging (DSI) for managing melanocytic lesions in patients treated with BRAF inhibitors, enabling precise identification and removal of high-risk naevi while reducing unnecessary excisions, thus streamlining patient care.
- Erbitux (cetuximab) / Eli Lilly
Cetuximab-Induced Papulopustular Exanthema: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2068;
During the first few weeks of treatment with EGFR inhibitors, papulopustular exanthema is the earliest and very common cutaneous side effect. The recognition and prompt management of cutaneous adverse effects may prevent severe, extensive symptoms, the need for dose reduction, or antitumor therapy interruption.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
The Double Trouble: Acne and Pyogenic Granuloma in EGFR Inhibitor Treatment (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2008;
They can significantly impact patient quality of life, leading to physical discomfort, psychological distress, and treatment interruptions. The skin adverse reactions during EGFR inhibitors treatment, appear to be mechanism-based linked to the inhibition of EGFR action but the exact pathophysiology remains elusive.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, BRCA Biomarker: Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective. (Pubmed Central) - Aug 5, 2024
We found that translesion polymerases are co-regulated with DNA mismatch repair and cell cycle-associated factors. We did not, however, identified any networks specific to cetuximab treatment indicating that the response to EGFR inhibitors relates to a general stress response mechanism.
- || TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Metastases: Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review. (Pubmed Central) - Aug 2, 2024
Our systematic review supports the use of a variety of therapy combinations for LA HNSCC cisplatin-ineligible patients. We highlight the urgent need for clinical studies assessing treatment approaches in this population.
- | cabazitaxel / Generic mfg.
Preclinical, Journal: Anti-EGFR immunoliposomes for cabazitaxel delivery: From formulation development to in vivo evaluation in prostate cancer xenograft model. (Pubmed Central) - Jul 31, 2024
While cabazitaxel induced leukopenia, consistent with clinical findings, histological analysis revealed no evident toxicity. In conclusion, the immunoliposomes displayed suitable physicochemical properties for cabazitaxel delivery, exhibited cytotoxicity against EGFR-expressing prostate cancer cells, with high cell uptake, and induced significant tumor regression in vivo, with manageable systemic toxicity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Metastases: Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Pubmed Central) - Jul 29, 2024
Although this was a relatively small retrospective study, it provides preliminary indications of the potential role of the STAT3 pathway on outcome in SCCHN and confirms that PTPRT acts as a negative regulator of STAT3. Our findings warrant investigation in a larger patient cohort to determine if inactivating this pathway through specific targeted treatments could improve outcomes in recurrent/metastatic SCCHN patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Combination therapy, Metastases: BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. (Pubmed Central) - Jul 29, 2024
Our findings warrant investigation in a larger patient cohort to determine if inactivating this pathway through specific targeted treatments could improve outcomes in recurrent/metastatic SCCHN patients. This case offers novel insights into the clinical behaviors of BRAF non-V600E-mCRC, potentially advancing personalized therapy for rare and aggressive cases.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
P3 data, Journal, Surgery, Patient reported outcomes: Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. (Pubmed Central) - Jul 28, 2024
This case offers novel insights into the clinical behaviors of BRAF non-V600E-mCRC, potentially advancing personalized therapy for rare and aggressive cases. The addition of cetuximab to CRT for the nonoperative management of esophageal cancer did not improve PROs.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. (Pubmed Central) - Jul 28, 2024
FOLFIRINOX+cetuximab provides good PFS, high response rate and prolonged disease control in initially unresectable extended RAS wild-type mCRC. This combination is particularly interesting for selected patients with liver-limited disease eligible to secondary resection.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Retrospective data, Journal, Metastases: Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. (Pubmed Central) - Jul 26, 2024
This combination is particularly interesting for selected patients with liver-limited disease eligible to secondary resection. In summary, the CAPOX regimen may be the safest option among the first-line systemic treatment regimens for mCRC patients, while the FOLFOXIRI?+?panitumumab regimen may be associated with a higher incidence of grade 3 or higher AEs.
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (clinicaltrials.gov) - Jul 24, 2024
P2, N=35, Recruiting, Sponsor: Pfizer
In summary, the CAPOX regimen may be the safest option among the first-line systemic treatment regimens for mCRC patients, while the FOLFOXIRI?+?panitumumab regimen may be associated with a higher incidence of grade 3 or higher AEs. Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
- HMBD-001 / Hummingbird Biosci
Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2522;
Exploratory analysis of genomic alterations in the MAPK and PI3K pathways will be performed and correlated with ORR. Enrollment of patients into the first stage of the study is currently ongoing.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Personalized Vascularized Models of Breast Cancer Desmoplasia Reveal Biomechanical Determinants of Drug Delivery to the Tumor. (Pubmed Central) - Jul 23, 2024
Similar responses are observed in patient-derived models. These microphysiological systems can thus be personalized by using patient-derived cells and can be applied to discover new molecular therapies for the normalization of the tumor microenvironment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, xevinapant (Debio 1143) / EMD Serono
Enrollment change, Trial suspension: XXL_2022-01: Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (clinicaltrials.gov) - Jul 17, 2024
P3, N=19, Suspended, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
These microphysiological systems can thus be personalized by using patient-derived cells and can be applied to discover new molecular therapies for the normalization of the tumor microenvironment. N=538 --> 19 | Recruiting --> Suspended
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Surgery: Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck. (Pubmed Central) - Jul 16, 2024
Progression-free survival (PFS) of the total population on median follow-up of 2.4 years (range: 0.8-7.3) tended to be better in the IC-PCE group (2-year PFS: 55.6% in the IC-PCE group vs. 33.3% in the CRT group, log-rank p=0.176), especially in oral cancer (2-year PFS: 37.5% in the IC-PCE group vs. 0% in the CRT group, log-rank p=0.015). Therapeutic strategies including IC-PCE in patients with unresectable locoregional recurrent SCCHN after curative surgery may contribute to improved prognosis, especially in oral cancer.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report. (Pubmed Central) - Jul 15, 2024
Despite discontinuing binimetinib due to myalgia, she had a long-term response with a progression-free survival of 14 months and an overall survival of more than 27 months. A chemotherapy protocol for BRAF-mutated metastatic colorectal cancer may be a treatment option for BRAF V600E-mutated colorectal NEC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Alpha-Gal Syndrome: An Underrated Serious Disease and a Potential Future Challenge. (Pubmed Central) - Jul 15, 2024
Sensitized individuals may also develop anaphylaxis after ingesting food and medicine or being exposed to medical equipment containing ?-gal, such as cetuximab and gelatin. Here, the literature on AGS is reviewed for a better understanding of its pathogenesis, clinical diagnosis, and treatment.
- | AG1478 / IDT Australia, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: PAR2 activation on human tubular epithelial cells engages converging signaling pathways to induce an inflammatory and fibrotic milieu. (Pubmed Central) - Jul 15, 2024
Whilst an EGFR blocking antibody, cetuximab, blocked PAR2 induced EGFR and ERK phosphorylation, a TGF-?RII blocking antibody failed to influence PAR2 induced secretion of PAI-1...In summary PAR2 activates critical inflammatory and fibrotic signalling pathways in human kidney tubular epithelial cells. Biased antagonists of PAR2 should be explored as a potential therapy for CKD.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance. (Pubmed Central) - Jul 13, 2024
Despite evidence that RAC1 and its alternative splice isoform RAC1B play important roles in CRC and the pathways known to contribute to cetuximab resistance, there is a need to directly study the relationship between RAC1 and RAC1B and cetuximab resistance. This review highlights the recent studies investigating RAC1 and RAC1B in the context of CRC and suggests that these proteins could play a role in resistance to cetuximab.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. (Pubmed Central) - Jul 13, 2024
In summary, before initiating cetuximab treatment, sIgE to alpha-gal should be assessed in all patients. To predict the severity of the reaction and to assess the risk of cetuximab-induced anaphylaxis, we should perform BATs with alpha-gal or more discriminative BATs with cetuximab.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal: Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance. (Pubmed Central) - Jul 13, 2024
Organoids can reflect tumor genetic heterogeneity found in the tissue of origin, representing a unique tool for personalized medicine. Thus, CRC-derived organoid cultures are a smart model for studying the tumor microenvironment and for the preclinical assay of anti-EGFR drugs.
- | Journal, Metabolomic study: Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics. (Pubmed Central) - Jul 12, 2024
Cells treated with a combination of subtoxic doses of trametinib and BKM120, an inhibitor of the PI3K pathway, showed a synergistic response between the two pathways...RS metabolites were verified with mass spectrometry, and enrichment pathways were identified, including amino acid, purine, and nicotinate and nicotinamide metabolism that differentiated monotherapy from combination therapy. Our approach may ultimately be applicable to patient-derived primary cells and cultures of patient tumors to predict effective drugs for individualized care.
- | Keytruda (pembrolizumab) / Merck (MSD), ImmuFact (eftilagimod alpha) / Immutep
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Jul 12, 2024
Our approach may ultimately be applicable to patient-derived primary cells and cultures of patient tumors to predict effective drugs for individualized care. Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in 2nd line HNSCC patients, thus supporting further evaluation of this combination in earlier treatment lines.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. (Pubmed Central) - Jul 10, 2024
Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in 2nd line HNSCC patients, thus supporting further evaluation of this combination in earlier treatment lines. The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical data, Journal, Metastases: Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care. (Pubmed Central) - Jul 10, 2024
The CET + FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC. It facilitates the suppression of STMs, ameliorates the serum inflammatory microenvironment, and enhances QOL, without increased adverse drug effects.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Beyond its preferential niche: Brucella abortus RNA down-modulates the IFN-?-induced MHC-I expression in epithelial and endothelial cells. (Pubmed Central) - Jul 9, 2024
Neutralization of the EGFR to some extent reversed the down-modulation of MHC-I mediated by Ba RNA in HMEC and A-549 cells. In conclusion, this is the first study exploring a central immune evasion strategy, such as the downregulation of MHC-I surface expression, beyond monocytes and could shed light on how it persists effectively within the host, enduring unseen and escaping CD8+ T cell surveillance.
- | 5-fluorouracil / Generic mfg.
Journal, Prognostic test: Cholangiocarcinoma, sequential chemotherapy, and prognostic tests. (Pubmed Central) - Jul 9, 2024
The next sequential additions are day 1, Cetuximab 400 total mg, then 200 mg weekly, and then Bevacizumab 10 mg/kg is substituted for Cetuximab (FDA IND# 119005)...Two-year survival is replicable and predictable. Findings warrant phase III validation tests of sequential regimens, re-challenge with recombination, low dosages, and blood tests that are associated with lethal mechanisms that impair response and survival.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Retrospective data, Journal, Metastases: Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. (Pubmed Central) - Jul 8, 2024
Findings warrant phase III validation tests of sequential regimens, re-challenge with recombination, low dosages, and blood tests that are associated with lethal mechanisms that impair response and survival. In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Real-world evidence, Real-world, Metastases: Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab. (Pubmed Central) - Jul 8, 2024
This real-world cohort of mCRC patients treated with encorafenib-cetuximab showed a clinically relevant efficacy-effectiveness gap for OS. The chance of survival benefit from encorafenib-cetuximab in patients with brain metastases and/or WHO performance status ?2 is negligible as neither efficacy nor effectiveness has been demonstrated.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1/2 data, Journal, Metastases: Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3). (Pubmed Central) - Jul 8, 2024
P1/2
The recommended doses, determined during the phase I part, could explain these disappointing results due to a reduction in chemotherapy dose-intensity. This trial was registered with EudraCT number 2006-004770-27.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Checkpoint inhibition, Metastases: Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer. (Pubmed Central) - Jul 6, 2024
In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3. (Pubmed Central) - Jul 5, 2024
Mechanistic studies revealed miR-135b-5p regulates the epithelial-to-mesenchymal transition (EMT) process and Wnt/?-catenin signaling pathway through downgulating FOXN3. In short, knockdowning miR-135b-5p could increase FOXN3 expression in CRC cells, promote the EMT process, and simultaneously activate the Wnt/?-catenin signaling pathway to elevate CTx resistance in CRC cells.
- ||| PF-07934040 / Pfizer
Enrollment open, Combination therapy, IO biomarker, Metastases: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - Jul 4, 2024
P1, N=330, Recruiting, Sponsor: Pfizer
In short, knockdowning miR-135b-5p could increase FOXN3 expression in CRC cells, promote the EMT process, and simultaneously activate the Wnt/?-catenin signaling pathway to elevate CTx resistance in CRC cells. Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review. (Pubmed Central) - Jul 4, 2024
However, no studies have investigated whether correcting hypomagnesemia can lead to the suppression of arrhythmias as a clinical outcome. Weak evidence suggests that Mg supplementation, as a preventive measure when developing hypomagnesemia following the initiation of anti-EGFR antibody therapy, may prevent the worsening of hypomagnesemia, and subsequently prevent associated arrhythmia occurrence.